<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955212</url>
  </required_header>
  <id_info>
    <org_study_id>M15-557</org_study_id>
    <nct_id>NCT02955212</nct_id>
  </id_info>
  <brief_title>A Study With Upatacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 multicenter study that includes two periods. Period 1 is a 12-week,
      randomized, double-blind, parallel-group, placebo-controlled period designed to compare the
      safety and efficacy of upadacitinib versus placebo for the treatment of signs and symptoms of
      participants with moderately to severely active RA who are on a stable dose of csDMARDs and
      have an inadequate response to csDMARDs. Period 2 is an open label 52 week extension period
      to evaluate the long-term safety, tolerability, and efficacy of upadacitinib in participants
      with RA who have completed Period 1.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">September 10, 2020</completion_date>
  <primary_completion_date type="Actual">August 14, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving American College of Rheumatology (ACR) 20 response</measure>
    <time_frame>At Week 12</time_frame>
    <description>ACR20 response rate will be determined based on 20% or greater improvement in tender joint count (TJC) and swollen joint count (SJC) and &gt;= 3 of the 5 measures of Patient's Assessment of Pain (VAS), Patient's Global Assessment of Disease Activity (VAS), Physician's Global Assessment of Disease Activity (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI), or high-sensitivity C-reactive protein (hsCRP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Short form-36 (SF-36) Physical Component Score (PCS)</measure>
    <time_frame>At Week 12</time_frame>
    <description>SF-36 is a 36 item participant questionnaire with questions regarding participant health and daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in disease activity score (DAS) 28 C-reactive protein (CRP) (Period 1)</measure>
    <time_frame>At Week 12</time_frame>
    <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving low disease activity (LDA) based on DAS28 (CRP) &lt;= 3.2</measure>
    <time_frame>At Week 12</time_frame>
    <description>Proportion of participants achieving low disease activity as defined by a clinical response DAS28[CRP] less than or equal to 3.2. The DAS28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score greater than 5.1 indicates high disease activity, a DAS28 score less than or equal to 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 70 Response Rate</measure>
    <time_frame>At Week 12</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving clinical remission (CR)</measure>
    <time_frame>At Week 12</time_frame>
    <description>CR based on DAS28 (CRP) response rate is defined as DAS28 (CRP) less than 2.6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving LDA based on CDAI ≤ 10</measure>
    <time_frame>At Week 12</time_frame>
    <description>Clinical Disease Activity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) (Period 1)</measure>
    <time_frame>At Week 12</time_frame>
    <description>HAQ-DI is a participant questionnaire with questions regarding the participant's illness and how it affect their daily life activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 20 response rate</measure>
    <time_frame>At Week 1</time_frame>
    <description>Change from baseline in individual components of ACR response at Week 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 50 Response Rate</measure>
    <time_frame>At Week 12</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">338</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Placebo (Period 1) followed by Upadacitinib (Period 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in Period 1, followed by upadacitinib which will be administered in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Upadacitinib (Period 1) followed by Upadacitinib (Period 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upadacitinib will be administered in Periods 1 and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Oral formulation once daily</description>
    <arm_group_label>Placebo (Period 1) followed by Upadacitinib (Period 2)</arm_group_label>
    <arm_group_label>Upadacitinib (Period 1) followed by Upadacitinib (Period 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral formulation once daily</description>
    <arm_group_label>Placebo (Period 1) followed by Upadacitinib (Period 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Rheumatoid Arthritis (RA) for &gt;= 3 months who also fulfill the 2010
             American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR)
             classification criteria for RA.

          -  Participants have been receiving csDMARD therapy &gt;= 3 months and on a stable dose for
             &gt;= 4 weeks prior to the first dose of study drug.

               1. Participants must have failed (lack of efficacy) at least one of the following:
                  methotrexate (MTX), sulfasalazine, or leflunomide.

               2. The following csDMARDs are allowed: oral or parenteral MTX, sulfasalazine,
                  hydroxychloroquine, chloroquine, and leflunomide.

               3. A combination of up to two background csDMARDs is allowed except the combination
                  of MTX and leflunomide.

          -  Participant meets both of the following disease activity criteria:

               1. &gt;= 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68
                  joint counts) at Screening and Baseline Visits; and

               2. High-sensitivity C-Reactive Protein (hsCRP) &gt;= upper limit of normal at Screening
                  Visit

          -  Participants with prior exposure to at most one bDMARD may be enrolled (up to 20% of
             total number of subjects). Specifically, prior to enrollment:

               1. Participants with limited exposure to Biological disease-modifying anti-rheumatic
                  drugs (bDMARD) (&lt; 3 months) OR

               2. Participants who are responding to a bDMARD therapy but had to discontinue due to
                  intolerability (regardless of treatment duration).

          -  Participants must have discontinued bDMARD therapy prior to the first dose of study
             drug.

        The washout period for bDMARDs prior to the first dose of study is specified below or at
        least five times the mean terminal elimination half-life of a drug:

          -  ≥ 4 weeks for etanercept;

          -  ≥ 8 weeks for adalimumab, infliximab, certolizumab, golimumab, abatacept, and
             tocilizumab;

          -  ≥ 1 year for rituximab OR ≥ 6 months if B cells have returned to pre-treatment level
             or normal reference range if pre-treatment levels are not available.

          -  For all other bDMARDs, contact the TA MD for the washout period required prior to the
             first dose of study drug.

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  Participants who are considered inadequate responders (lack of efficacy) to bDMARD
             therapy as defined by the Investigator.

          -  History of any arthritis with onset prior to age 17 years or current diagnosis of
             inflammatory joint disease other than RA (including but not limited to gout, systemic
             lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing
             spondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlap
             connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia
             [currently with active symptoms]. Current diagnosis of secondary Sjogren's Syndrome is
             permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ceti - Centro de Estudos Em Terapias Inovadoras Ltda /Id# 152964</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parana Medical Research Center /ID# 153507</name>
      <address>
        <city>Maringa</city>
        <state>Parana</state>
        <zip>87015-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMK Sevicos Medicos S/S /ID# 152963</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90480-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 152961</name>
      <address>
        <city>Sao Jose Do Rio Preto</city>
        <state>Sao Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos Ltda /ID# 152966</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Aff Hosp of Bengbu Med Col /ID# 162161</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233099</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital /ID# 161117</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hosp. of Fudan Uni. /ID# 161108</name>
      <address>
        <city>Shanghai</city>
        <state>Anhui</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 1st Aff Hosp Xiamen Univ /ID# 162154</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhuzhou Central Hospital /ID# 162153</name>
      <address>
        <city>Zhuzhou</city>
        <state>Hunan</state>
        <zip>412007</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital /ID# 163747</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital /ID# 168462</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Jiujiang /ID# 168461</name>
      <address>
        <city>Jiujiang</city>
        <state>Jiangxi</state>
        <zip>332000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hosp of Jilin Univ /ID# 161116</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jining No.1 People's Hospital /ID# 162158</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>272001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital /ID# 161123</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital /ID# 161119</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hosp Capital Med Univ /ID# 161118</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Med College Hosp /ID# 161107</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University /ID# 162152</name>
      <address>
        <city>Changsha</city>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University /ID# 164637</name>
      <address>
        <city>Kunming</city>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital /ID# 161122</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pingxiang People's Hospital /ID# 162151</name>
      <address>
        <city>Pingxiang</city>
        <zip>337055</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Aff Hosp of Shantou Univ /ID# 162165</name>
      <address>
        <city>Shantou, Guangdong</city>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Shanxi /ID# 162164</name>
      <address>
        <city>Taiyuan</city>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Med Univ General Hosp /ID# 162155</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Xinjiang /ID# 162157</name>
      <address>
        <city>Urumqi</city>
        <zip>830001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University /ID# 162150</name>
      <address>
        <city>Xi'an</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SoonChunHyang University CheonAn Hospital /ID# 209078</name>
      <address>
        <city>Cheonan-si</city>
        <state>Chungcheongnamdo</state>
        <zip>31151</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National Univ Hosp /ID# 166919</name>
      <address>
        <city>Daegu</city>
        <state>Daegu Gwang Yeogsi</state>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital /ID# 167727</name>
      <address>
        <city>Jung-gu</city>
        <state>Daejeon Gwang Yeogsi</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital /ID# 163912</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggido</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital /ID# 166918</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggido</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital /ID# 163910</name>
      <address>
        <city>Jung-gu</city>
        <state>Incheon Gwang Yeogsi</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital /ID# 167726</name>
      <address>
        <city>Gwangju</city>
        <state>Jeonranamdo</state>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Medical Center /ID# 163908</name>
      <address>
        <city>Dongdaemun-gu</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center /ID# 163911</name>
      <address>
        <city>Dongjak-gu</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital /ID# 168421</name>
      <address>
        <city>Seodaemun-gu</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospi /ID# 163913</name>
      <address>
        <city>Seongdong-gu</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Ctr /ID# 206148</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Yeouido St. Mary's Hospital /ID# 204224</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>07345</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center /ID# 163909</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hostipal /ID# 209076</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)</keyword>
  <keyword>ABT-494</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <pending_results>
    <submitted>July 27, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

